ArticleOrphanet journal of rare diseases2026
Multidimensional assessment of diaphragmatic dysfunction in late-onset Pompe disease: a prospective cohort study.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Late-onset Pompe disease (LOPD) often leads to progressive respiratory failure due to diaphragmatic involvement. Conventional pulmonary function tests frequently fail to detect early respiratory muscle weakness. We conducted a five-year prospective cohort study of 15 genetically confirmed LOPD patients to evaluate diaphragmatic function using a multidimensional approach that included spirometry, inspiratory/expiratory pressures (MIP/MEP), sniff nasal inspiratory pressure (SNIP), arterial blood gases, and diaphragmatic ultrasound. Data were analyzed using generalized linear mixed models. Forced vital capacity (FVC) declined progressively (− 1.05% per visit, p = 0.010), while diaphragmatic thickening fraction (TF, − 3.46% per visit, p < 0.0001), SNIP (− 2.53 cmH₂O per visit, p = 0.003), and MIP (− 3.56% per visit, p < 0.001) showed earlier and steeper declines. TF and SNIP were significantly more sensitive than FVC in detecting early respiratory involvement (p < 0.05). Patients receiving enzyme replacement therapy (ERT) had slower functional decline, with significantly higher SNIP values (p = 0.003). One patient developed symptomatic diaphragmatic weakness despite preserved FVC. SNIP and TF are more sensitive than FVC for early detection of respiratory dysfunction in LOPD and may allow earlier initiation of enzyme replacement therapy and respiratory support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.